Access to Salbutamol Inhalers Debate
Full Debate: Read Full DebateAlex Norris
Main Page: Alex Norris (Labour (Co-op) - Nottingham North and Kimberley)Department Debates - View all Alex Norris's debates with the Department of Health and Social Care
(2 years, 9 months ago)
Westminster HallWestminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
It is a pleasure to serve under your chairmanship, Mr Hosie. I am grateful for the chance to speak for the Opposition in this important debate.
I start, like others, by paying tribute to the young chef Lauren Reid, whose tragic passing last year has led to this debate. Described by her mum as
“the most amazing, kind, beautiful and caring person”,
may we turn this family’s heartache into action and look at ways we can prevent this from happening again.
I also pay tribute to Lauren’s mum, Elaine, who has been spearheading this campaign, and I send my thoughts and prayers to Lauren’s family and friends. I also send them to her colleagues. Hearing what the hon. Member for Don Valley (Nick Fletcher) said about their experience in that moment, and their efforts, I send them my solidarity, too.
Securing a debate through the petition route is a very hard thing to do—100,000 signatures is an awful lot. That speaks to the seriousness of this case, and to how strongly people feel about it. I commend those who promoted it and organised it, and all those who signed it.
The hon. Gentleman had the difficult job of opening this poignant debate, and I thought he did a very good job and made a thoughtful case. I was particularly struck by two things, which I might also speak about. The first was the context of asthma in this country, and the second was the risks in commercial kitchens, which is what, beyond the broader national messages about asthma, makes this individual case very compelling.
There were similarly thoughtful contributions from other colleagues. The hon. Member for Rutherglen and Hamilton West (Margaret Ferrier) set out just how common asthma is. It behoves us, as a national legislature, to act on behalf of that significant portion of our population. I agree with her comments against the argument that those at risk should change roles—I do not give that view much succour, either. I would not want to give up my dreams for something that a reasonable adjustment could prevent, and I would not want anybody else to do that, either.
We look forward to the upcoming debate on asthma secured by the hon. Member for Strangford (Jim Shannon), where we will be able to continue talking about some of these themes. He made very interesting points about schools, which offer an analogous example—a read-across—showing that what Elaine and her family are asking for is working somewhere else. That is very useful. Moreover, I think we all share the hon. Gentleman’s views on safeguards, because we are conscious of the risk regarding prescription drugs.
At the root of this issue is a simple argument, which is to permit the availability of salbutamol inhalers in commercial kitchens. This campaign is backed by Unichef—the chef’s union—and others, such as GMB, my trade union. They are calling for an exemption to be made, whereby commercial kitchens can be supplied with inhalers and administer them in emergencies. In their response, the Government have said that that is something that the regulator would need to approve, and if it sees a benefit a public consultation will be launched. I hope that the Minister will update us on the progress of her discussions with the licensing authority. Similarly, has she engaged with the Royal Pharmaceutical Society about the production of draft guidance once the licencing authority has finished its consideration? It would be very interesting to know what progress has been made in the period between the Government’s official response to the petition and today.
Turning to asthma more generally, 57% of healthcare professionals have had patients who have had an asthma attack or needed emergency care because, for whatever reason, they did not have their medication with them. Life happens: these are errors that any of us could make, particularly when living busy lives, and as we have heard, this is a big group of people. Some 5.4 million people in the UK are receiving treatment for asthma, leading to 41,000 hospital admissions last year due to asthma-related concerns alone, and 1,300 deaths. That is a really significant issue and it requires significant action in this place. As the hon. Member for Airdrie and Shotts (Ms Qaisar) has said, the rate of asthma deaths has increased recently, and we are an outlier relative to our neighbours, with a death rate that is 50% higher than the average in the European Union. Again, we are called upon to understand the challenges in our country and to look at what we might do differently, and this is certainly one of the things we could do differently.
As numerous hon. Members have said, the reason why the distinct setting of a commercial kitchen deserves special consideration is that it is a potentially risky environment, with triggers such as flour, fumes, heat, dust, odours and a lack of decent ventilation. It is perfectly reasonable for us to consider whether we might do better in that setting, because everybody should be safe at work and have safety nets to help them. The example in the case of schools is clear: it has been possible to make an exemption in schedule 17 to the Human Medicines Regulations 2012 to allow the sale and supply of salbutamol inhalers and EpiPens to schools for use in emergencies, so the petition is not asking for something that cannot be done.
I will make a couple of very brief points about the regulator itself. We in this country are very well served by the Medicines and Healthcare products Regulatory Agency, which will be an exceptionally important body for all of us at some point in our lives. Whatever medicine or medical device we may need, the MHRA is the regulator that tells us that it is safe for us to use, so we all rely on it. However, it is also a very busy regulator. The pace of change in that market is significant, both domestically and globally, and recently we in this place have put a significant number of new responsibilities on the MHRA through the Medicines and Medical Devices Act 2021, which received Royal Assent earlier this year. That Act was, in part, a response to our exit from the European Union and the change in the regulatory environment that arose from it. The MHRA is on a high wire and it is not overhyping it to say that it has a life-and-death job, but we are going to make a 20% cut to its staff. The MHRA’s income from the European Union has dried up so we are reducing its staff, yet we are asking it to do more, and that cannot be wise. I hope that the Minister will reflect on that and assure us that Ministers are actively looking at that decision so as to ensure that that cut does not happen, because it does not support patient safety in this country.
To conclude, it is right that we first listen to the MHRA before we act, but the petition’s proposal is reasonable and, because it has a comparative example, feasible. I hope that the Minister will address my questions and those of colleagues, and give us a sense of the conversations taking place and of the timetable, because people are watching today’s debate. I hope they will feel that we have done this really important issue justice—I think we have—but they will want to know where it goes next, so I hope we will hear that from the Minister.